ATNAHS PHARMA US
Big PharmaATNAHS PHARMA US is a major pharmaceutical company focused on Immunology.
ATNAHS PHARMA US's Key Drugs
ATNAHS PHARMA US's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ATNAHS PHARMA US's Recent FDA Approvals
New NDA/BLA approvals for ATNAHS PHARMA US over the last two years — novel drugs only, excluding generics and label supplements.
ATNAHS PHARMA US's Therapeutic Areas
ATNAHS PHARMA US's approved drugs and pipeline span 1 therapeutic area, led by Immunology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ATNAHS PHARMA US's Top Competitors
ATNAHS PHARMA US's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ATNAHS PHARMA US Pipeline Snapshot
Active clinical trials for ATNAHS PHARMA US across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1976-03-11
- Latest
- 2024-11-21
- Applications
- 5